Novo Nordisk A/S (NVO)
| Market Cap | 215.00B |
| Revenue (ttm) | 49.58B |
| Net Income (ttm) | 16.30B |
| Shares Out | 4.44B |
| EPS (ttm) | 3.67 |
| PE Ratio | 12.99 |
| Forward PE | 13.12 |
| Dividend | $1.23 (2.59%) |
| Ex-Dividend Date | Aug 18, 2025 |
| Volume | 15,225,021 |
| Open | 49.50 |
| Previous Close | 49.00 |
| Day's Range | 47.48 - 49.53 |
| 52-Week Range | 45.05 - 112.52 |
| Beta | 0.35 |
| Analysts | Buy |
| Price Target | 60.50 (+27.1%) |
| Earnings Date | Nov 5, 2025 |
About NVO
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrin... [Read more]
Financial Performance
In 2024, Novo Nordisk's revenue was 290.40 billion, an increase of 25.03% compared to the previous year's 232.26 billion. Earnings were 100.99 billion, an increase of 20.68%.
Financial numbers in DKK Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for NVO stock is "Buy." The 12-month stock price target is $60.5, which is an increase of 27.10% from the latest price.
News
Novo Nordisk: One Of The Most Mispriced Alphas In The Market
Novo Nordisk (NVO) is deeply undervalued after a 43% YTD decline, despite strong fundamentals and global obesity market leadership. NVO dominates international markets with 72% share and 335% Wegovy s...
Novo Nordisk: Will Wegovy And Pipeline Spark Rally?
Novo Nordisk is quietly coming out of the storm despite the prevailing pessimism, especially among retail investors. Thanks to Wegovy's approval as a treatment for NASH, its sales rose to DKK 20.35 bi...
Novo Nordisk: Potential Winner With Value Trap Risks
NVO's discounted valuations and promising oral candidate may trigger a drastic reversal in its stock prices/performance, upon the materialization of positive catalyst/bullish support. This is signific...
Obesity-drugmaker Novo Nordisk helps drive Denmark's fastest growth in years
Denmark's seasonally adjusted gross domestic product grew by 2.3% in the third quarter, a preliminary reading from Statistics Denmark showed early Thursday. The main driver of growth was the pharmaceu...
Focus: High-stakes Novo Nordisk Alzheimer's studies could yield answers on GLP-1 benefit
Studies from Novo Nordisk due early next month will give the strongest indication yet of whether blockbuster GLP-1 drugs - a class being used by millions for diabetes and weight loss - can slow progre...
Researchers move closer to matching patients with GLP-1 drug that works best for them
U.S. researchers are beginning to identify clinical characteristics that distinguish “super responders” to GLP-1 weight-loss drugs like Wegovy and Zepbound from patients who lose only moderate amounts...
Novo Nordisk: A Rare Second Chance
Novo Nordisk is rated a 'Strong Buy' due to its undervaluation, wide economic moat, and long-term growth prospects despite recent setbacks. Novo Nordisk's Q3/25 results showed slowing growth, lowered ...
Novo Nordisk: Modeling A GLP-1 Giant In Retreat And Recovery
Novo Nordisk faces intensifying GLP-1 competition, notably from Eli Lilly, prompting price cuts for Wegovy to expand market access and defend share. NVO's long-term upside relies on broadening semaglu...
Novo Holdings to sell 7.8% stake in UK's Convatec, bookrunner says
Novo Holdings, which controls obesity drugmaker Novo Nordisk , will sell 155 million shares, or about 7.8% of its stake, in British medical products maker Convatec Group , a bookrunner for the offerin...
Novo Nordisk, Eli Lilly Weight Loss Price War Heats Up. Why It's a Worry for the Stocks.
Signs of a weight loss price war appeared to worry investors early Monday, and Lilly and Novo stocks were down.
Novo Nordisk is now offering its anti-obesity drug for as low as $199 per month
Novo Nordisk (NYSE: NVO) has announced sweeping price cuts for its blockbuster GLP-1 drugs, Wegovy and Ozempic, offering patients access to the lowest doses for just $199/month. New cash-paying patien...
Monthly Ozempic Cost Slashed After Trump Deal
Novo Nordisk and Eli Lilly will lower the price Medicare pays for their GLP-1 treatments, which cost up to $1,350 per month before insurance, to $245 per month. Patients using the new TrumpRx.gov to p...
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
Bagsværd, Denmark, 17 November 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated per...
Novo Nordisk Cuts Prices for Obesity Drugs
The Denmark-based company slashed prices for the first two monthly doses of Wegovy and Ozempic for those who pay cash for the treatments between Nov. 17 and March 31.
Novo Nordisk cuts direct-to-consumer prices for Wegovy, Ozempic to $349 a month
Novo Nordisk said it is lowering the direct-to-consumer prices of its blockbuster weight loss drug Wegovy and diabetes counterpart Ozempic to $349 per month from $499 per month for existing cash-payin...
Novo Nordisk rolls out $349 Wegovy cash price ahead of plan
Novo Nordisk said on Monday it has begun selling its popular weight-loss drug Wegovy for $349 a month to cash payers, months ahead of the timeline set out with the Trump administration.
Novo Nordisk CEO says White House deal aims to bring Wegovy to Medicare patients
Wegovy-maker Novo Nordisk's CEO said on Monday a deal with the White House to slash prices on its popular weight‑loss drugs aimed to broaden access to the U.S. Medicare programme, a federal health ins...
PGIM Jennison Health Sciences Fund Q3 2025 Contributors And Detractors
The S&P 1500 Health Care Index advanced 4.0% in the third quarter, underperforming the S&P 500, which gained 8.1%. Stock selection within biotechnology and health care providers & services, along with...
Novo Nordisk Stock: Buy And Forget
Novo Nordisk A/S shares have declined more than 50% over the past 12 months. Competition in the obesity and type 2 diabetes market and pricing pressure from the U.S. government have weighed on NVO res...
Biopharma companies have confidence in their ability to do deals: BMO's Evan Seigerman
Evan Seigerman, BMO Capital Markets head of health care research, joins 'Power Lunch' to discuss what's behind the recent move in health care stocks, the state of play with GLP-1s and much more.
Novo Nordisk shareholders approve new board chair
Novo Nordisk's shareholders have approved Lars Rebien Sorensen as the company's new chairman in an extraordinary shareholder meeting, the company said on Friday.
Novo Nordisk's leadership strategy tested as shareholders signal frustration ahead of vote on board revamp
Novo Nordisk last month announced an Extraordinary General Meeting for Nov. 14 to replace its independent board members. The weight-loss drugmaker has found itself in an increasingly chaotic situation...
Novo Nordisk Says Mikael Dolsten Won't Seek Election to Board at Friday's Meeting
The drugmaker is holding a special shareholder meeting to vote on the appointment of a new board after the pharma giant lost its lead in the obesity-drug market.